C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 6,152 | 11,016 | 11,230 | 6,463 | 7,238 |
| Gross Profit | 6,152 | 11,016 | 11,230 | 6,463 | 7,238 |
| Operating Expenses | 33,937 | 34,161 | 45,642 | 34,964 | 36,402 |
| Operating Income | -27,785 | -23,145 | -34,412 | -28,501 | -29,164 |
| Interest Expense | -2,656 | -5,026 | 0 | -2,481 | -2,842 |
| Other Income | 0 | -2,246 | 2,246 | 0 | 0 |
| Pre-tax Income | -25,129 | -20,365 | -32,166 | -26,020 | -26,322 |
| Net Income Continuous | -25,129 | -20,486 | -32,166 | -26,020 | -26,322 |
| Net Income | $-25,129 | $-20,486 | $-32,166 | $-26,020 | $-26,322 |
| EPS Basic Total Ops | -0.20 | -0.09 | -0.44 | -0.37 | -0.37 |
| EPS Basic Continuous Ops | -0.20 | -0.09 | -0.44 | -0.37 | -0.37 |
| EPS Diluted Total Ops | -0.20 | -0.09 | -0.44 | -0.37 | -0.37 |
| EPS Diluted Continuous Ops | -0.20 | -0.09 | -0.44 | -0.37 | -0.37 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.18 | -0.44 | -0.37 | -0.37 |
| EBITDA(a) | $-28,470 | $-23,580 | $-34,467 | $-28,467 | $-29,491 |